What the FDA labels say about taking them together
Erythromycin and risperidone
Risperidone's FDA label of May 28, 2026 names erythromycin in its drug interactions section; the erythromycin labels PlainMeds reads (4) do not name risperidone. The risperidone label: “Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS).”
Check it at the source: the erythromycin FDA label on DailyMed (effective August 1, 2024, Teva Pharmaceuticals USA, Inc.); the risperidone FDA label on DailyMed (effective May 28, 2026, Janssen Pharmaceuticals, Inc.).
What does the erythromycin label say about risperidone?
Erythromycin's label (effective August 1, 2024) and its 3 other brand-application labels do not name risperidone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Erythromycin), Teva Pharmaceuticals USA, Inc., effective August 1, 2024 (SPL set 75a0bd5a-d09f-483b-bfd8-f8343b149eb2), via openFDA; the full label on DailyMed
What does the risperidone label say about erythromycin?
Risperidone label, drug interactionsDose adjustment is not recommended for RISPERDAL when co-administered with ranitidine, cimetidine, amitriptyline, or erythromycin [see Table 18 ].
Risperdal Consta label (Janssen Pharmaceuticals, Inc., November 5, 2025), drug interactionsErythromycin There were no significant interactions between oral RISPERDAL and erythromycin.
Rykindo Extended-Release Microspheres label (Shandong Luye Pharmaceutical Co., Ltd., May 26, 2026), drug interactionsClinical Impact: Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS). … concomitantly with amitriptyline, cimetidine, ranitidine, clozapine, topiramate and moderate CYP3A4 inhibitors (erythromycin). Additionally, no dosage adjustment is necessary for lithium, valproate, topiramate, digoxin and CYP2D6 substrates (donepezil and galantamine) when co-administered with RYKINDO [ see …
Source: FDA drug label (Risperdal Consta, NDA021346), Janssen Pharmaceuticals, Inc., effective November 5, 2025 (SPL set bb34ee82-d2c2-43b8-ba21-2825c0954691), via openFDA
Source: FDA drug label (Rykindo Extended-Release Microspheres, NDA212849), Shandong Luye Pharmaceutical Co., Ltd., effective May 26, 2026 (SPL set 58534c96-96f5-4c2e-a061-92d4506aee91), via openFDA
Source: FDA drug label (Risperidone, NDA020588), Janssen Pharmaceuticals, Inc., effective August 20, 2026 (SPL set 701e1cd8-2868-4d29-85a9-a2212c88165f), via openFDA
Source: FDA drug label (RISPERDAL), Janssen Pharmaceuticals, Inc., effective May 28, 2026 (SPL set 7e117c7e-02fc-4343-92a1-230061dfc5e0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Erythromycin | Risperidone | |
|---|---|---|
| Labeled for | Bacterial infections, Acne | Bipolar disorder, Schizophrenia |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.96 per tablet 250 mg tablet | $0.0368 per tablet 0.25 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once